Continuation of Natalizumab in Multiple Sclerosis Patients

Rationale for Continuation

The American Academy of Neurology recommends that patients with multiple sclerosis who are clinically stable on natalizumab should continue therapy, as discontinuation can lead to disease reactivation or rebound, increasing morbidity 1, 2

The National Multiple Sclerosis Society guidelines suggest that patients with multiple sclerosis who are JC virus positive should be monitored closely, and that continuation of natalizumab therapy is supported as long as proper risk stratification and monitoring are in place 1, 3, 4
The European Committee for Treatment and Research in Multiple Sclerosis recommends that patients with multiple sclerosis who are at high risk of progressive multifocal leukoencephalopathy (PML) should be considered for extended interval dosing of natalizumab, which can potentially reduce PML risk while maintaining efficacy 2, 5

The American Academy of Neurology recommends that patients with multiple sclerosis who are receiving natalizumab therapy should undergo regular JC virus antibody testing, and that MRI monitoring should be conducted according to risk stratification, with high-risk patients requiring more frequent monitoring 3, 6, 7
The National Multiple Sclerosis Society guidelines suggest that clinical evaluation should continue at regular intervals, with a minimum of every 6 months, to monitor for signs of disease activity or progression 8

The Food and Drug Administration (FDA) label for natalizumab indicates that it is approved for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, regardless of documented MS subtype 9, 10
The European Committee for Treatment and Research in Multiple Sclerosis recommends that patients with multiple sclerosis who are clinically stable on natalizumab should continue therapy, as abrupt discontinuation can lead to severe disease reactivation, increasing morbidity and mortality risk 10

Risk stratification for PML should include anti-JCV antibody status and index value, treatment duration, and prior immunosuppressant use, as recommended by the Journal of Neurology, Neurosurgery and Psychiatry 11
MRI monitoring frequency should be adapted based on JCV status, with JCV antibody-positive patients requiring more frequent monitoring, such as minimum 6-monthly MRI after 18 months of treatment for those with index ≤1.5, and 3-4 monthly MRI after 18 months of treatment for those with index >1.5 11
Patients with high anti-JCV antibody indices (>1.5) have significantly higher PML risk, approximately 1 in 855, compared to JCV antibody-negative patients, approximately 1 in 10,000 11

JCV antibody positivity with an index value of 0.6 places a patient in a moderate risk category for Progressive Multifocal Leukoencephalopathy (PML), with an estimated risk of approximately 1 in 5,882, according to the Journal of Neurology, Neurosurgery and Psychiatry 12, 13
For JCV antibody-positive patients with index values ≤1.5, guidelines recommend MRI monitoring at minimum every 6 months after 18 months of treatment, and continued JCV antibody index testing every 6 months, as suggested by the Journal of Neurology, Neurosurgery and Psychiatry 12, 13

The patient's current monitoring plan should include regular JCV antibody testing, MRI brain and cervical spine monitoring, and regular neurological assessments, as recommended by the Journal of Neurology, Neurosurgery and Psychiatry 12
Enhanced MRI monitoring should be implemented, with follow-up MRIs scheduled at least every 6 months for patients with index values < 1.5, according to the Journal of Neurology, Neurosurgery and Psychiatry 12, 13
JCV antibody monitoring should be continued, with rechecking of the JCV antibody index every 6 months, and increase of MRI frequency to every 3-4 months if the index rises above 1.5, as suggested by the Journal of Neurology, Neurosurgery and Psychiatry 12, 13